Gastritis, Peptic Ulcer Disease and H. pylori Pharmacotherapy

Connect the causes, mucosal injury, pathology, clinical presentation, diagnosis and treatment of acid-peptic disease for rapid KMU-oriented revision.

Concept Integration structure aligned with the supplied AIM specification. :contentReference[oaicite:0]{index=0}

1. THE TOPIC IN ONE CONNECTED FLOW

Gastritis and peptic ulcer disease develop when damaging influences exceed normal gastric mucosal defenses. H. pylori, NSAIDs, chemical injury and autoimmune mechanisms disturb protection in different ways. The resulting mucosal injury produces recognizable pathological changes, clinical symptoms and complications, while treatment acts by removing the cause, reducing acid or strengthening mucosal defense.

Cause / Trigger

H. pylori, NSAIDs, chemical injury or autoimmunity

→

Core Mechanism

Inflammation or loss of mucus, bicarbonate, blood flow and prostaglandin protection

→

Tissue Change

Gastritis, erosion, glandular atrophy or deep peptic ulcer

→

Clinical Presentation

Epigastric pain, dyspepsia, nausea or gastrointestinal bleeding

→

Diagnostic Clue

H. pylori testing, endoscopy, biopsy or laboratory evidence of complications

→

Treatment Target

Suppress acid, protect mucosa, remove offending cause and eradicate H. pylori

→

Outcome

Healing or progression to bleeding, penetration, perforation or obstruction

2. KEY CLINICAL CONNECTIONS

Mucosal Injury → Pathology → Complication

H. pylori inflammation or NSAID-related prostaglandin loss → reduced mucosal defense → acid-peptic injury → chronic ulcer.

Deep extension → vessel erosion, adjacent-organ penetration, free perforation or fibrotic outlet narrowing.

H. pylori → Colonization → Diagnosis

Flagella + adhesins + urease → survival and attachment in gastric mucus → persistent inflammation and ulcer risk.

Active infection → stool antigen, urea breath test or biopsy-based testing; serology may remain positive after eradication.

Drug Target → Benefit → Important Caution

PPI → H⁺/K⁺-ATPase inhibition → strong acid suppression and ulcer healing; omeprazole may reduce clopidogrel activation.

Sucralfate or antacids → local GI action → drug-binding or chelation interactions, so timing matters.

3. AIM HIGH-YIELD INTEGRATION REVIEW

⭐ H. pylori colonization → chronic active gastritis → impaired mucosal defense and altered acid regulation → peptic ulcer risk.

NSAIDs → cyclo-oxygenase inhibition → reduced prostaglandins → less mucus, bicarbonate and blood flow → mucosal injury.

⭐ Autoimmune parietal-cell injury → reduced acid and intrinsic factor → hypergastrinemia plus risk of vitamin B12 deficiency.

Chronic peptic ulcer → necrotic debris + inflammation + granulation tissue + fibrosis → healing with scar formation.

⭐ Urea breath or stool antigen testing → evidence of active H. pylori → useful for diagnosis and eradication assessment.

Campylobacter → curved microaerophilic gram-negative bacillus → mainly enteric disease, whereas H. pylori is the gastric ulcer-associated organism.

⭐ PPIs → irreversible proton-pump inhibition → strongest routine acid suppression; H2 blockers mainly reduce histamine-mediated basal and nocturnal secretion.

H. pylori eradication → acid suppression + multiple antimicrobials ± bismuth → treatment of both mucosal injury and the infectious cause.

AIM Exam Trap: Healing of an ulcer does not prove eradication of H. pylori; confirm eradication with a test that detects active infection rather than antibody serology.

Gastritis, Peptic Ulcer Disease and H. pylori Pharmacotherapy

1. THE TOPIC IN ONE CONNECTED FLOW

2. KEY CLINICAL CONNECTIONS

3. AIM HIGH-YIELD INTEGRATION REVIEW

Install AIM App